Investment Thesis
Ainos is a financially distressed pharmaceutical company experiencing severe operational deterioration with revenue collapsing 83% YoY while burning cash at an alarming rate. The company's negative operating margin of -8574.8% and free cash flow of -3.8M indicate unsustainable operations with minimal revenue generation relative to expenses. With only 1.1M in cash and ongoing cash burn, the company faces imminent liquidity crisis unless it can dramatically reverse its business trajectory.
AIMDW Strengths
- Positive gross margin of 82.6% suggests potential product profitability if revenue scales
- Current ratio of 2.96x provides short-term liquidity cushion
- Zero long-term debt eliminates refinancing risk
AIMDW Risks
- Revenue collapsed 83% YoY with only 113K in trailing revenue, indicating complete loss of market demand
- Operating cash flow of -3.8M with only 1.1M in cash provides less than 3 months of runway at current burn rate
- Negative ROE of -102.6% and ROA of -45.4% demonstrate value destruction and operational failure
- Operating margin of -8574.8% indicates the company cannot support its cost structure with current revenue levels
- Dramatic EPS deterioration to -2.61 despite modest YoY improvement signals ongoing value destruction
Key Metrics to Watch
- Monthly cash burn rate and cash runway duration
- Revenue stabilization and return to growth trajectory
- Operating expense reduction initiatives or restructuring plans
- Product pipeline clinical trial progress and commercialization timelines
AIMDW Financial Metrics
AIMDW Profitability Ratios
AIMDW Balance Sheet & Liquidity
AIMDW 5-Year Financial Trend
5-Year Trend Summary: Ainos, Inc.'s revenue has grown significantly by 637% over the 5-year period, indicating strong business expansion. The most recent EPS of $-3.36 indicates the company is currently unprofitable.
AIMDW Growth Metrics (YoY)
AIMDW Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.2K | -$2.9M | $-0.64 |
| Q2 2025 | $4.7K | -$3.2M | $-0.99 |
| Q1 2025 | $20.7K | -$3.3M | $-0.21 |
| Q3 2024 | $20.7K | -$3.0M | $-0.33 |
| Q2 2024 | $20.7K | -$2.3M | $-0.49 |
| Q1 2024 | $20.7K | -$2.5M | $-0.57 |
| Q3 2023 | $24.5K | -$3.0M | N/A |
| Q2 2023 | $28.6K | -$2.0M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
AIMDW Capital Allocation
AIMDW SEC Filings
Access official SEC EDGAR filings for Ainos, Inc. (CIK: 0001014763)